• Home
  • Search Results

Search Results

Cancer - Leukemia
72 studies match your search
By physician referral or invitation only

Diagnostic Delay

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 11 more)
Visit Location
100% Remote (online, phone, text)

enCompass Carolina: A social support and coaching program for cancer caregivers

Cancer caregivers experience high levels of stress related to the caregiving role, particularly for rural caregivers. The purpose of this study is to assess the acceptability and preliminary effect of enCompass Carolina, a social support program for caregivers of rural-dwelling patients with cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Mental and Emotional Health
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Age & Gender
  • 0 days ~ 22 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

cGVHD study

Collecting data on chronic GVHD instances

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
  • Immune System/Infections
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Social Intervention for young adults with cancer

we will be conducting 60-minute interviews with young adults to hear about social connections (in person and online) and cancer support on social media

Age & Gender
  • 22 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Leukemia

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

ACCL1931 - Levocarnitine as Prophylaxis for Hepatotoxicity in AYA (15-39.9) with de novo ALL/Lly/MPAL

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

Age & Gender
  • 15 years ~ 39.9 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Leukemia)
  • Kidneys and Liver
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

This is a study evaluating whether the use of an electronic web-based tool containing surveys could support patients and doctors make better treatment decisions together. New patients, 60 years or older, will be randomized to either receive the tool or not. Surveys will be collected from patients about their experience in making treatment decisions to evaluate whether the tool was beneficial.

Age & Gender
  • 60 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

A study to test if the addition of Inotuzumab Ozogamicin (InO) to standard chemotherapy treatment in patients diagnosed with National Cancer Institute (NCI) High-Risk (HR) B-cell Acute Lymphoblastic Leukemia (B-ALL) or NCI Standard-Risk (SR) B- ALL with high risk features improves outcomes.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

Age & Gender
  • 1 years ~ 24 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

UNC Cancer Radiation Therapy Registry

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research